{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperthyroidism/prescribing-information/beta-blockers/","result":{"pageContext":{"chapter":{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers","depth":2,"htmlHeader":"<!-- begin field 311fecce-d926-45ce-8920-5745ce85a4c4 --><h2>Beta-blockers</h2><!-- end field 311fecce-d926-45ce-8920-5745ce85a4c4 -->","summary":"","htmlStringContent":"<!-- begin item c5169419-6087-4e9f-8b6f-5b57357690d5 --><!-- end item c5169419-6087-4e9f-8b6f-5b57357690d5 -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","lastRevised":"Last revised in January 2021","chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","fullItemName":"Management","slug":"management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"621a1415-df2a-5ffd-a873-e007eff19df6","slug":"choice-of-beta-blocker","fullItemName":"Choice of beta-blocker","depth":3,"htmlHeader":"<!-- begin field 9d6c78c0-e299-4ccb-ae45-4138005ce3da --><h3>Choice of beta-blocker</h3><!-- end field 9d6c78c0-e299-4ccb-ae45-4138005ce3da -->","summary":"","htmlStringContent":"<!-- begin item 2a3c9241-df29-42ee-b90b-568c3bb75622 --><!-- begin field 5e8cd434-1fc1-4e9e-b89f-45519d9bacd5 --><ul><li>The beta-blockers propranolol (used most commonly), metoprolol, and nadolol are licensed for the treatment of thyrotoxicosis as an adjunct to antithyroid drug treatment.</li></ul><p><strong>Table 1.</strong> Beta-blockers licensed for use in thyrotoxicosis </p><table><thead><tr><th colspan=\"1\" scope=\"col\">Beta-blocker</th><th colspan=\"1\" scope=\"col\">Licensed doses</th></tr></thead><tbody><tr><td colspan=\"1\">Propranolol</td><td colspan=\"1\">10–40 mg three to four times a day.</td></tr><tr><td colspan=\"1\">Metoprolol</td><td colspan=\"1\">50 mg four times a day.</td></tr><tr><td colspan=\"1\">Nadolol</td><td colspan=\"1\">80–160 mg once a day.</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 5e8cd434-1fc1-4e9e-b89f-45519d9bacd5 --><!-- end item 2a3c9241-df29-42ee-b90b-568c3bb75622 -->","subChapters":[]},{"id":"2e293f9c-bf00-521c-b04d-e5c95b84e467","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9d0dee1e-bb63-4f6d-ad1d-427076e86e1e --><h3>Contraindications and cautions</h3><!-- end field 9d0dee1e-bb63-4f6d-ad1d-427076e86e1e -->","summary":"","htmlStringContent":"<!-- begin item a99a24e2-0c7a-473f-8b95-e76b0f593664 --><!-- begin field c9139ab6-71fb-4d80-b3b8-3bde7b4c1129 --><ul><li><strong>Beta-blockers should not be prescribed to people with:</strong><ul><li>Asthma.</li><li>Uncontrolled heart failure.</li><li>Prinzmetal's angina.</li><li>Marked bradycardia.</li><li>Hypotension.</li><li>Sick sinus syndrome.</li><li>Second- or third-degree atrio-ventricular (AV) block.</li><li>Cardiogenic shock.</li><li>Metabolic acidosis.</li><li>Severe peripheral arterial disease.</li><li>Phaeochromocytoma.</li></ul></li><li><strong>Beta-blockers should be prescribed with caution to people with:</strong><ul><li>First-degree AV block.</li><li>Diabetes mellitus — symptoms of hypoglycaemia may be masked.</li><li>Chronic obstructive pumonary disease — introduce cautiously and monitor lung function.</li><li>Myasthenia gravis.</li><li>Psoriasis.</li><li>History of hypersensitivity — may increase sensitivity to allergens and may result in a more serious hypersensitivity response.</li><li>Renal impairment — dose reduction may be required.</li><li>Hepatic impairment — reduce the dose.</li><li>Portal hypertension (risk of deterioration in liver function).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field c9139ab6-71fb-4d80-b3b8-3bde7b4c1129 --><!-- end item a99a24e2-0c7a-473f-8b95-e76b0f593664 -->","subChapters":[]},{"id":"d9911f8d-1348-5daf-b080-764d04d71c35","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 52c480eb-5359-43c5-bcd3-ccf110dc332b --><h3>Adverse effects</h3><!-- end field 52c480eb-5359-43c5-bcd3-ccf110dc332b -->","summary":"","htmlStringContent":"<!-- begin item ff7c4ed5-b1f0-4b62-9ab9-0a17b6b94541 --><!-- begin field 1e5e87d8-806d-4e8d-8044-5a49968bbee8 --><ul><li><strong>Adverse effects of beta-blockers include:</strong><ul><li>Fatigue, cold extremities.</li><li>Bradycardia, syncope, heart failure, hypotension, conduction disorders, peripheral vasoconstriction (including exacerbation of intermittent claudication and Raynaud's phenomenon).</li><li>Bronchospasm, dyspnoea, headache, fatigue, sleep disturbance.</li><li>Paraesthesia, dizziness, vertigo, confusion, depression.</li><li>Psychosis, sexual dysfunction, visual disturbances, dry eyes, exacerbation of psoriasis, alopecia.</li><li>Purpura, thrombocytopenia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field 1e5e87d8-806d-4e8d-8044-5a49968bbee8 --><!-- end item ff7c4ed5-b1f0-4b62-9ab9-0a17b6b94541 -->","subChapters":[]},{"id":"593f0cbb-dbf7-50e4-8ea3-13996b0f4524","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6a19b627-b124-4753-81ec-1ab51374a8d5 --><h3>Drug interactions</h3><!-- end field 6a19b627-b124-4753-81ec-1ab51374a8d5 -->","summary":"","htmlStringContent":"<!-- begin item 2e5ee815-4f2e-4348-abd9-ff4ad7199472 --><!-- begin field fb69da19-a83e-44c2-893c-8bc38b94b093 --><ul><li><strong>Drug interactions with beta-blockers include:</strong><ul><li>Angio-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists (AIIRAs) — enhanced hypotensive effect.</li><li>Alcohol — enhanced hypotensive effect.</li><li>Alpha-blockers — enhanced hypotensive effect; also increased risk of first-dose hypotension when given with alpha-blockers such as prazosin.</li><li>Amiodarone — increased risk of bradycardia, atro-ventricular (AV) block, and myocardial depression.</li><li>Anti-arrhythmics — increased risk of myocardial depression.</li><li>Antidiabetic drugs — beta-blockers may mask warning signs of hypoglycaemia, such as tremor.</li><li>Calcium-channel blockers — enhanced hypotensive effect.</li><li>Clonidine — increased risk of withdrawal hypertension.</li><li>Corticosteroids — hypotensive effect of beta-blockers antagonized by beta-blockers.</li><li>Diltiazem — increased risk of AV block and bradycardia.</li><li>Diuretics — enhanced hypotensive effect.</li><li>Insulin — beta-blockers enhance hypoglycaemic effect of insulin.</li><li>Methyldopa — enhanced hypotensive effect.</li><li>Minoxidil — enhanced hypotensive effect.</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) — hypotensive effect of beta-blockers antagonized by NSAIDs.</li><li>Nifedipine — possible severe hypotension and heart failure.</li><li>Nitrates — enhanced hypotensive effect.</li><li>Oestrogens — hypotensive effect of beta-blockers antagonized by oestrogens.</li><li>Verapamil — asystole, severe hypotension, and heart failure.</li></ul></li><li><strong>Specific drug interactions with propranolol include:</strong><ul><li>Chlorpromazine — plasma concentration of both drugs may increase.</li><li>Cimetidine — plasma concentration of propranolol increased.</li><li>Imiprimine — propranolol increases plasma concentration of imiprimine.</li><li>Levothyroxine — metabolism of propranolol accelerated by levothyroxine.</li></ul></li><li><strong>Specific drug interactions with metoprolol include:</strong><ul><li>Cimetidine — plasma concentration of metoprolol increased.</li><li>Citalopram and escitalopram — plasma concentration of metoprolol increased.</li><li>Mirabegron — plasma concentration of metoprolol increased.</li><li>Paroxetine — plasma concentration of metoprolol possibly increased; increased risk of AV block.</li></ul></li><li><strong>Specific drug interactions with nadolol include:</strong><ul><li>Ketoconazole — plasma concentration of nadolol possibly increased.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hyperthyroidism/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field fb69da19-a83e-44c2-893c-8bc38b94b093 --><!-- end item 2e5ee815-4f2e-4348-abd9-ff4ad7199472 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}